Randomized, open-label study of bintrafusp alfa vs. pembrolizumab as first-line (1L) treatment in patients with PD-L1-expressing advanced non-small cell lung cancer (NSCLC)
Ahn, M. -., Barlesi, F., Felip, E., Garon, E., Martin, C. M., Vokes, E., et al. (2021). Randomized, open-label study … Read More